These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously ...

Imnn Stock- Imunon’s stock surged 179% after positive Phase 2 ovarian cancer trial results and plans for a Phase 3 study ...

Imunon (IMNN) stock rocketed higher on Friday after the pharmaceutical company announced positive results from its Phase 2 OVATION 2 Study of IMNN-001. This study was focused on using IMNN-001 as a ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...

Imunon Inc (NASDAQ:IMNN) stock surged 172% in premarket trading after the company announced significant survival data from its Phase 2 trial of IMNN-001, a treatment for newly diagnosed advanced ...

Imunon Inc. soared by 179% on the heels of phase II Ovation 2 data showing that its IMNN-001 immunotherapy led to a 13-month increase in overall survival among women with ovarian cancer. Patients in ...

Fintel reports that on May 19, 2025, D. Boral Capital downgraded their outlook for Imunon (NasdaqCM:IMNN) from Buy to Hold.

On May 8, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first trial site for the Phase 3 OVATION 3 trial has been activated and is ready to begin enrolling patients. During the quarterly ...

It also underscores the scientific community's strong and historic evidence of IMNN-001 anti-cancer cancer potential. We believe we have much to offer the future of oncology treatment. And I hope ...